Topotarget is a Scandinavian-based oncology
company focused on late-stage clinical development. Topotarget aims
at improving the quality of life and prolonging the lives of cancer
patients by offering novel, safe, and effective cancer
drugs. Our lead compound, belinostat, is a Histone Deacetylase
(HDAC) inhibitor that is
being tested in a number of clinical trials.